Clinical Trials Directory

Trials / Completed

CompletedNCT03407105

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

A Phase I, Open-Label, Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

Conditions

Interventions

TypeNameDescription
BIOLOGICALMDX-010Specified dose on specified days

Timeline

Start date
2003-04-21
Primary completion
2006-02-21
Completion
2006-02-21
First posted
2018-01-23
Last updated
2018-01-23

Locations

5 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03407105. Inclusion in this directory is not an endorsement.

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficienc (NCT03407105) · Clinical Trials Directory